Optimization of Dose Regimen for ALXN1210, a Novel Complement C5 Inhibitor, in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results of 2 Phase 1/2 Studies
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.3482.3482
Abstract: Background : ALXN1210 is a rationally designed humanized monoclonal antibody to complement component 5 (C5), engineered to achieve extended half-life and duration of complement inhibition while retaining the proven efficacy and safety of eculizumab. Objective… read more here.
Keywords: pharmaceuticals inc; alexion pharmaceuticals; induction; complement inhibitor ... See more keywords
Use of the complement inhibitor Coversin to treat HSCT-associated TMA.
Sign Up to like & getrecommendations! Published in 2017 at "Blood advances"
DOI: 10.1182/bloodadvances.2016002832
Abstract: Finding an inherited complement abnormality in HSCT-associated TMA provides a rationale for the use of a complement inhibitor.Alternative complement inhibitors such as Coversin should be considered in patients who are resistant to eculizumab. read more here.
Keywords: complement inhibitor; complement; associated tma; hsct associated ... See more keywords
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Sign Up to like & getrecommendations! Published in 2023 at "Blood advances"
DOI: 10.1182/bloodadvances.2022009129
Abstract: Key Points • Complement inhibitor–naive patients with PNH had greater hemoglobin stabilization and LDH reduction with pegcetacoplan vs control.• Pegcetacoplan’s comprehensive control of hemolysis and favorable safety profile in these patients may help expand the… read more here.
Keywords: hemolysis; complement inhibitor; inhibitor naive; pegcetacoplan controls ... See more keywords
Complement Inhibitor Therapy for Myasthenia Gravis
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2020.00917
Abstract: Complement activation as a driver of pathology in myasthenia gravis (MG) has been appreciated for decades. The terminal complement component [membrane attack complex (MAC)] is found at the neuromuscular junctions of patients with MG. Animals… read more here.
Keywords: complement inhibitor; inhibitor therapy; therapy myasthenia; complement ... See more keywords